1 Sutherland M,Ahmed O,Zaidi A,et al.Current progress in systemic therapy for biliary tract cancers[J].J Hepatobiliary Pancreat Sci,2021,10:1002. 2 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(2):394-424. 3 Banales JM,Cardinale V,Carpino G,et al.Expert consensus document:Cholangiocarcinoma:current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma(ENS-CCA)[J].Nat Rev Gastroenterol Hepatol,2016,13:261-280. 4 Lamarca A,EdelinE J,Mcnamara MG,et al.Current standards and future perspectives in adjuvant treatment for biliary tract cancers[J].Cancer Treat Rev,2020,84:101936. 5 Kim BH,Kim E,Kim K,et al.The impact of perioperative CA19-9 change on the survival and recurrence patterns after adjuvant chemoradiotherapy in resectable extrahepatic cholangiocarcinoma[J].J Surg Oncol,2018,117:380-388. 6 Groot Koerkamp B,Wiggers JK,Gonen M,et al.Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram[J].Ann Oncol,2016,27(4):753. 7 Horgan AM,Amir E,Walter T,et al.Adjuvant therapy in the treatment of biliary tract cancer:a systematic review and meta-analysis[J].J Clin Oncol,2012,30(16):1934-1940. 8 Ghidini M,Tomasello G,Botticelli A,et al.Adjuvant chemotherapy for resected biliary tract cancers:a systematic review and meta-analysis[J].HPB(Oxford),2017,19(9):741-748. 9 Wang L,Deng M,Ke Q,et al.Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma:a multicenter retrospective study[J].Cancer Med,2020,9(8):2674-2685. 10 Altman AM,Kizy S,Marmor S,et al.Adjuvant chemotherapy for intrahepatic cholangiocarcinoma:approaching clinical practice consensus?[J].Hepatobiliary Surg Nutr,2020,9(5):577-586. 11 Cloyd JM,Pawlik TM.Trends in the use of adjuvant therapy for resected intrahepatic cholangiocarcinoma:getting ahead of the data[J].Hepatobiliary Surg Nutr,2021,10(4):515-517. 12 Woo SM,Yoon KA,Hong EK,et al.DCK expression,a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection:results from a phase II study[J].Oncotarget,2017,8(46):81394-81404. 13 Kainuma O,Miura F,Furukawa D,et al.Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer[J].J Hepatobiliary Pancreat Sci,2015,22(11):789-794. 14 Siebenhüner AR,Seifert H,Bachmann H,et al.Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine:A prospective single center phase II study[J].BMC Cancer,2018,18(1):72. 15 Ebata T,Hirano S,Konishi M,et al.Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer[J].Br J Surg,2018,105(3):192-202. 16 Edeline J,Benabdelghani M,Bertaut A,et al.Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer(PRODIGE 12-ACCORD 18-UNICANCER GI):a randomized phase III study[J].J Clin Oncol,2019,37:658-667. 17 Kim KP,Jang G,Hong YS,et al.Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer:influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity[J].Br J Cancer,2011,104(4):605-612. 18 Yoo C,Han B,Kim HS.et al.Multicenter phase II study of oxaliplatin,irinotecan,and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer[J].Cancer Res Treat,2018,50(4):1324-1330. 19 Obayashi S,Nagano H,Tomokuni A,et al.A prospective,randomized phase II study of adjuvant gemcitabine versus S-1 after major hepatectomy for biliary tract cancer(KHBO 1208):Kansai Hepato-Biliary Oncology Group[J].Ann Surg,2019,270(2):230-237. 20 Seita K,Ebata T,Mizuno T,et al.Phase 2 trial of adjuvant chemotherapy with S-1 for node-positive biliary tract cancer(N-SOG 09)[J].Ann Surg Oncol,2020,27(7):2348-2356. 21 Nakachi K,Konishi M,Ikeda M,et al.A randomized phase III trial of adjuvant S-1 therapy vs.observation alone in resected biliary tract cancer:Japan Clinical Oncology Group Study(JCOG1202,ASCOT)[J].Jpn J Clin Oncol,2018,48(4):392-395. 22 Song S,Yang W,Tian H,et al.The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer:a systematic review and meta-analysis[J].Clin Res Hepatol Gastroenterol,2022,46(2):101788. 23 Primrose JN,Fox RP,Palmer DH,et al.Capecitabine compared with observation in resected biliary tract cancer(BILCAP):a randomised,controlled,multicentre,phase 3 study[J].Lancet Oncol,2019,20:663-673. 24 Chen X,Meng F,Xiong H,et al.Adjuvant therapy for resectable biliary tract cancer:a bayesian network analysis[J].Front Oncol,2021,11:600027. 25 Takahashi D,Mizuno T,Yokoyama Y,et al.Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma:a propensity score-adjusted analysis[J].J Hepatobiliary Pancreat Sci,2021,28(9):716-726. 26 Stein A,Arnold D,Bridgewater J,et al.Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma(ACTICCA-1 trial)-a randomized,multidisciplinary,multinational phase III trial[J].BMC Cancer,2015,15:564. 27 Hyder O,Dodson RM,Sachs T,et al.Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma:a propensity score-matched Surveillance,Epidemiology,and End Results analysis[J].Surgery,2014,155(1):85-93. 28 Leng KM,Liu YP,Wang ZD,et al.Results of adjuvant radiation therapy for locoregional perihilar cholangiocarcinoma after curative intent resection[J].Onco Targets Ther,2017,10:2257-2266. 29 Ren B,Guo Q,Yang Y,et al.A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma[J].Radiat Oncol,2020,15(1):15. 30 Ben-Josef E,Guthrie KA,El-Khoueiry AB,et al.SWOG S0809:A phase ii intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma[J].J Clin Oncol,2015,33:2617-2622. 31 Shroff RT,Kennedy EB,Bachini M,et al.Adjuvant therapy for resected biliary tract cancer:ASCO clinical practice guideline[J].J Clin Oncol,2019,37(12):1015-1027. 32 Kobayashi S,Gotoh K,Takahashi H,et al.Clinicopathological features of surgically-resected biliary tract cancer following chemo-radiation therapy[J].Anticancer Res,2016,36(1):335-342. 33 Le Roy B,Gelli M,Pittau G,et al.Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J].Br J Surg,2018,105(7):839-847. 34 Sumiyoshi T,Shima Y,Okabayashi T,et al.Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma[J].World J Surg,2018,42(9):2910-2918. 35 Goetze TO,Bechstein WO,Bankstahl US,et al.Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC(ICC/ECC)-a phase III study of the German registry of incidental gallbladder carcinoma platform(GR)-the AIO/CALGP/ACO-GAIN-trial[J].BMC Cancer,2020,20(1):122. 36 JCOG1920:A phase III trial of neoadjuvant Gemcitabine + Cisplatin + S-1(GCS)vs.surgery first for resectable biliary tract cancer(NABICA T).https://jrct.niph.go.jp/en-latest-detail/jRCTs031200388. 37 Lin J,Cao Y,Yang X,et al.Mutational spectrum and precision oncology for biliary tract carcinoma[J].Theranostics,2021,11(10):4585-4598. 38 Yoo C,Shin SH,Park JO,et al.Current status and future perspectives of perioperative therapy for resectable biliary tract cancer:a multidisciplinary review[J].Cancers(Basel),2021,13(7):1647. |